ライフサイエンスコーパス: drug susceptibility test

1 detection of R5 and X4 HIV-1 replication and drug susceptibility tests.

2 ine complicates the development of molecular drug susceptibility tests.

3 ts, which our model had a 71% agreement with drug susceptibility testing.

4 sed recombination followed by sequencing and drug susceptibility testing.

5 a multifunctional assay for TB diagnosis and drug susceptibility testing.

6 owth Indicator Tube (MGIT) culture with MGIT drug susceptibility testing.

7 rapid diagnosis, therapeutic monitoring, and drug susceptibility testing.

8 % CI: 87.9-95.8) when compared to phenotypic drug susceptibility testing.

9 mprovement of turnaround time for phenotypic drug susceptibility testing.

10 nce was obtained and the results of in vitro drug susceptibility testing.

11 chelonae that were originally submitted for drug susceptibility testing.

12 losis identification, and from 55 to 75% for drug susceptibility testing.

13 stance was highly concordant with laboratory drug susceptibility testing.

14 hole-genome sequencing (WGS), and phenotypic drug susceptibility testing.

15 must be accelerated along with comprehensive drug susceptibility testing.

16 by side-effects and challenges with reliable drug susceptibility testing.

17 rowth indicator tube (MGIT) culture,and MGIT drug-susceptibility testing.

18 re in the same ranges as those of phenotypic drug-susceptibility testing.

19 eatment rely on access to rapid and reliable drug-susceptibility testing.

20 rogram (MPEP) for Mycobacterium tuberculosis Drug Susceptibility Testing, 1994 to 2008, implemented b

21 .49) as were those who did not have baseline drug-susceptibility tests (2.24; 1.31-3.83).

22 Based on the reference laboratory drug susceptibility test, 394 (62%) strains were pan-sus

23 erculosis (59%); and radiometric methods for drug susceptibility testing (55%).

24 Among 4826 (93.5%) with drug susceptibility testing, 82 (1.7%) had MDR-TB.

25 00%, respectively, compared to those of MGIT drug susceptibility testing, after the exclusion of syno

26 In drug susceptibility testing, all isolates of M. abscessu

27 blished through highly concordant laboratory drug susceptibility testing and in silico prediction met

28 o a composite reference standard (phenotypic drug susceptibility testing and line probe assay).

29 ing would accelerate access to comprehensive drug susceptibility testing and molecular typing.

30 predict treatment response than traditional drug susceptibility testing and open avenues for persona

31 We defined RMR TB found on initial drug susceptibility testing and possible acquired rifamp

32 with modifiable risk factors such as lack of drug susceptibility testing and suboptimal initial antit

33 mear-positive tuberculosis were subjected to drug susceptibility testing and to spoligotyping and var

34 correlating molecular data with results from drug susceptibility testing and, optimally, associated p

35 R) tuberculosis were evaluated by phenotypic drug-susceptibility testing and mutation detection metho

36 e discuss recent advances in diagnostics and drug-susceptibility testing and outline the progress in

37 However, further interventions, such as drug-susceptibility testing and standardised or individu

38 whole-genome sequencing, expanded phenotypic drug susceptibility testing, and enhanced case managemen

39 nd analyzed using smear microscopy, culture, drug susceptibility testing, and NAAT.

40 ltidrug-resistant tuberculosis, low rates of drug susceptibility testing, and poor access to antiretr

41 bacterial cultures, molecular and phenotypic drug susceptibility tests, and radiographic studies, amo

42 bacterial cultures, molecular and phenotypic drug susceptibility tests, and radiographic studies, amo

43 l growth indicator tube (MGIT) culture, MGIT drug-susceptibility testing, and the Xpert MTB/RIF assay

44 Laboratory facilities for drug susceptibility testing are inadequate in most tuber

45 To assess the value of phenotypic drug susceptibility testing as a predictor of antiretrov

46 specimen was compared with culture tests and drug susceptibility testing as reference standards.

47 We also used cultures, drug-susceptibility testing, bacterial genotyping, and m

48 These patients were referred for culture and drug susceptibility testing because of the clinical susp

49 d be useful for many applications, including drug susceptibility testing, but current technologies ha

50 Inaccurate drug susceptibility testing by comparison with a referen

51 Chest radiography and sputum culture drug susceptibility testing can assist physicians in pre

52 drugs and guided by genotypic and phenotypic drug susceptibility testing can improve treatment outcom

53 aired whole-genome sequencing and phenotypic drug susceptibility testing data were amassed from 45 co

54 t comprised of 35,777 Mtb WGS and phenotypic drug-susceptibility test data across first- and second-l

55 Drug susceptibility testing demonstrated a multidrug-res

56 CR are cultured, owing to higher-sensitivity drug susceptibility testing, differential diagnosis, and

57 o concordance or discordance of results from drug susceptibility testing done locally and in a refere

58 o concordance or discordance of results from drug susceptibility testing done locally and whole-genom

59 -2238M USD for a tuberculosis detection plus drug susceptibility test (DST) all-in-one or 1.5M tests/

60 ms of Mycobacterium tuberculosis However, no drug susceptibility test (DST) is considered sufficientl

61 ease treated with regimens tailored to their drug susceptibility test (DST) result or to the DST resu

62 lected cases for which the initial and final drug susceptibility test (DST) results had been reported

63 ure results with available initial and final drug susceptibility test (DST) results.

64 culosis (MDR-TB) in comparison with standard drug susceptibility testing (DST) and compared the resul

65 ing (WGS) has been widely used for genotypic drug susceptibility testing (DST) and outbreak investiga

66 rug regimens are creating new priorities for drug susceptibility testing (DST) and surveillance.

67 site reference standard that used phenotypic drug susceptibility testing (DST) and targeted sequencin

68 iagnostics, Ltd., United Kingdom) as a rapid drug susceptibility testing (DST) approach for diagnosin

69 The Genotype MTBDRplus(R), a rapid drug susceptibility testing (DST) assay used to detect r

70 concentration (MIC) testing, unlike routine drug susceptibility testing (DST) at a single critical c

71 g active tuberculosis (TB) and lack of rapid drug susceptibility testing (DST) at the point of care r

72 ltaneously, CDC does growth-based phenotypic drug susceptibility testing (DST) by the indirect agar p

73 icenter study was carried out to evaluate if drug susceptibility testing (DST) can be successfully ca

74 R alone for selected genotypic technologies) drug susceptibility testing (DST) followed, if necessary

75 hanisms of action, resistance emergence, and drug susceptibility testing (DST) for delamanid.

76 tuberculosis depends upon reliable and valid drug susceptibility testing (DST) for pyrazinamide, etha

77 Expanding access to culture and drug susceptibility testing (DST) for TB diagnosis may h

78 Conventional culture-based drug susceptibility testing (DST) for the second-line an

79 Universal drug susceptibility testing (DST) for tuberculosis is a

80 Noted issues with PZA Drug Susceptibility Testing (DST) have driven the search

81 Universal drug susceptibility testing (DST) is an important requir

82 Rapid tuberculosis (TB) drug susceptibility testing (DST) is crucial.

83 Rapid and comprehensive drug susceptibility testing (DST) is essential for diagn

84 Drug susceptibility testing (DST) is essential for start

85 cious treatments, validated and standardized drug susceptibility testing (DST) is required to improve

86 Comprehensive and reliable drug susceptibility testing (DST) is urgently needed to

87 Culture-based drug susceptibility testing (DST) may take 4 weeks or lo

88 Current growth-based drug susceptibility testing (DST) method takes 7 to 14 d

89 of this study was to establish standardized drug susceptibility testing (DST) methodologies and refe

90 ehensive alternative to existing methods for drug susceptibility testing (DST) of Mycobacterium tuber

91 tested using conventional liquid culture and drug susceptibility testing (DST) on solid medium and 10

92 fortunately, classic growth-based phenotypic drug susceptibility testing (DST) remains difficult, cos

93 regimen among US MDR-TB cases that had full drug susceptibility testing (DST) results and were repor

94 hs, which is currently needed for phenotypic drug susceptibility testing (DST) results.

95 ginal benefit for regimens based directly on drug susceptibility testing (DST) results.

96 Mycobacterium tuberculosis using phenotypic drug susceptibility testing (DST) to determine the exten

97 e isolates underwent standardized phenotypic drug susceptibility testing (DST) to isoniazid (INH), ri

98 However, the most appropriate use of drug susceptibility testing (DST) to support this regime

99 nal methods including AFB smear, culture and drug susceptibility testing (DST) using both an absolute

100 PZA drug susceptibility testing (DST) was performed directly

101 pecies level, concordance with culture-based drug susceptibility testing (DST), and turnaround time.

102 sed for mycobacterial culture and phenotypic drug susceptibility testing (DST), BD MAX and Xpert MTB/

103 as then processed for culture and phenotypic drug susceptibility testing (DST), BD MAX, and Xpert MTB

104 Phenotypic drug susceptibility testing (DST), the current reference

105 update and clarify policies on tuberculosis drug susceptibility testing (DST), the World Health Orga

106 to guide the development of molecular-based drug susceptibility testing (DST).

107 rains based on the agar proportion method of drug susceptibility testing (DST).

108 ral weeks for conventional culture-dependent drug susceptibility testing (DST).

109 ns largely standardized and based on limited drug susceptibility testing (DST).

110 oquinolone resistance (FQ-R) was detected on drug susceptibility testing (DST).

111 ncing of the erm(41), rrl, and rrs genes and drug susceptibility testing (DST).

112 diagnosis (sensitivity, 65.4%) and reliable drug susceptibility testing (DST).

113 erformance of the test to that of phenotypic drug susceptibility testing (DST).

114 ed 5-drug regimen while awaiting second-line drug-susceptibility test (DST) results.

115 A target product profile for a molecular drug-susceptibility test (DST) was developed on the basi

116 mple and accurate tests for TB diagnosis and drug-susceptibility testing (DST) in endemic regions.

117 If in addition, drug-susceptibility testing (DST) is available to inform

118 on requires evidence-based, context-specific drug-susceptibility testing (DST) strategies.

119 encing (WGS) has the potential to accelerate drug-susceptibility testing (DST) to design appropriate

120 BDQ phenotypic drug-susceptibility testing (DST) was performed for all

121 dence-based, context-specific strategies for drug-susceptibility testing (DST) will be required.

122 t followed by confirmatory test (TT), and 4) drug-susceptibility testing (DST).

123 of mycobacterial species, and culture-based drug-susceptibility testing (DST).

124 have phenotypic heterogeneity in results of drug-susceptibility tests (DSTs).

125 Most of the new drug susceptibility tests endorsed by the World Health O

126 Drug susceptibility testing established that ald loss of

127 product profiles set by the WHO for genetic drug susceptibility testing, except for rifampicin, for

128 rs a rapid, accurate, 1- to 3-day phenotypic drug susceptibility test for first- and second-line drug

129 eful as a rapid 3-day first- and second-line drug susceptibility test for M. tuberculosis.

130 culture-free, and antibiotic incubation-free drug susceptibility test for TB using Raman spectroscopy

131 by community health workers; and (4) a rapid drug susceptibility test for use at the microscopy cente

132 types of MYCOTB plates were used to perform drug susceptibility testing for 12 antibiotics (rifampic

133 Despite the WHO's call for universal drug susceptibility testing for all patients being evalu

134 (8%) of 38 patients assessable by phenotypic drug susceptibility testing for bedaquiline had primary

135 ompany scale-up of new drugs; however, rapid drug susceptibility testing for bedaquiline remains chal

136 Phenotypic drug susceptibility testing for bedaquiline was done on

137 cted to whole genome sequencing and standard drug susceptibility testing for eleven anti-TB drugs.

138 romising route to achieving rapid, universal drug susceptibility testing for Mycobacterium tuberculos

139 Improved diagnostics and drug susceptibility testing for Mycobacterium tuberculos

140 Universal access to drug susceptibility testing for newly diagnosed tubercul

141 Rapid genotype-based drug susceptibility testing for the Mycobacterium tuberc

142 ed culture-positive MTBC cases with reported drug susceptibility tests for PZA in 38 jurisdictions ro

143 TB burden setting suggested that a new rapid drug-susceptibility test for TB may be more practical fo

144 hese characterisations to predict phenotypic drug-susceptibility testing for an independent validatio

145 Drug-susceptibility testing for study purposes was done

146 We evaluated the accuracy of genotypic drug susceptibility testing (gDST) using publicly availa

147 While the goal of universal drug susceptibility testing has been a key component of

148 and the proportion using BACTEC for primary drug susceptibility testing has increased from 26.2 to 7

149 In contexts where use of drug susceptibility testing has not been universal (i.e.

150 Limited availability of drug susceptibility testing, high costs and inefficienci

151 y diagnosed tuberculosis patients, including drug susceptibility testing if performed, regimen assign

152 growth characteristics with biochemical and drug susceptibility tests; (ii). molecular techniques in

153 ion study for the introduction of this rapid drug susceptibility test in Kinshasa, Democratic Republi

154 by construction of cloned viral mutants and drug susceptibility testing in cell culture.

155 ould be accompanied by increased support for drug susceptibility testing in developing countries to b

156 sistant tuberculosis with sputum culture and drug susceptibility testing in patients with known or su

157 ons were not different than culture-based FQ drug susceptibility testing in predicting the hazard of

158 boratory systems through increased access to drug-susceptibility testing in Uganda.

159 nce was compared to gold-standard phenotypic drug susceptibility tests, including Lowenstein-Jensen (

160 t risk for multidrug-resistant tuberculosis, drug susceptibility testing is imperative to guide thera

161 Human immunodeficiency virus type 1 (HIV-1) drug susceptibility testing is often curtailed because s

162 rug susceptibility testing, yet conventional drug susceptibility testing is slow, and molecular testi

163 molecular diagnostics for tuberculosis (TB) drug-susceptibility testing is critical to inform treatm

164 Phenotypic drug-susceptibility testing is slow and expensive, and c

165 a 48 h luciferase reporter mycobacteriophage drug susceptibility testing (LRM-DST) assay using TM4::G

166 to the cumbersome nature of the conventional drug susceptibility testing method using mouse footpad i

167 st below the resolving capability of current drug susceptibility testing methodologies, and may expla

168 Molecular drug susceptibility testing methods provide considerable

169 nce to AMK and KAN in all three conventional drug susceptibility testing methods.

170 For isoniazid and rifampin drug susceptibility testing, MODS is as accurate as and

171 Rapid molecular drug susceptibility test of first-line and second-line d

172 eference MIC quality control (QC) ranges for drug susceptibility testing of antimycobacterials, inclu

173 spectroscopy for accurate few-to-single-cell drug susceptibility testing of BCG.

174 riptase sequencing, protease sequencing, and drug susceptibility testing of HIV-1.

175 ted growth and detection of mycobacteria and drug susceptibility testing of Mycobacterium tuberculosi

176 Conventional indirect drug susceptibility testing of Mycobacterium tuberculosi

177 own to be useful for the rapid detection and drug susceptibility testing of Mycobacterium tuberculosi

178 fection treatment-tailored to the results of drug susceptibility testing of the putative source case-

179 Drug susceptibility tests of recombinant patient isolate

180 We performed whole genome sequencing and drug susceptibility testing on 337 clinical isolates of

181 of viable M. paratuberculosis cells, such as drug susceptibility testing or environmental survival st

182 table drugs (SLIDs) compared with phenotypic drug susceptibility testing (pDST) and whole-genome sequ

183 Although rarely performed, phenotypic drug susceptibility testing (pDST) is used to define PZA

184 Although rarely performed, phenotypic drug susceptibility testing (pDST) is used to define PZA

185 ented by rpoB gene sequencing and phenotypic drug-susceptibility testing (pDST), serving as reference

186 The drug susceptibility testing performance of a broth-based

187 rsed catalogue of molecular targets for MTBC drug susceptibility testing provides a global standard f

188 enotype to anti-TB drugs were obtained using drug susceptibility testing recommended by the World Hea

189 Tailoring the TB regimen to each patient's drug susceptibility test results and burden of disease a

190 ined mortality during treatment according to drug susceptibility test results and treatment adequacy

191 amikacin, kanamycin, or capreomycin based on drug susceptibility test results from initial and follow

192 Disease Control and Prevention in 1993 added drug susceptibility test results to the information coll

193 More than 50% of secondary cases with drug susceptibility test results were concordant with th

194 regression models, compared with concordant drug susceptibility test results, the adjusted odds rati

195 with crude risks varying greatly by initial drug susceptibility test results: 1 in 1909 if initially

196 The rate of reproducibility of the drug susceptibility testing results between the particip

197 specificity of 100% relative to conventional drug susceptibility testing results for RIF resistance.

198 ing assay for M. tuberculosis and phenotypic drug susceptibility testing results when available.

199 ype patterns of M. tuberculosis strains with drug-susceptibility test results and epidemiologic infor

200 d the proportion of household contacts whose drug-susceptibility test results matched those of the pu

201 were 1800 patients with culture-positive TB, drug-susceptibility test results, and genotyping results

202 cterial isolates that may dictate to conduct drug susceptibility test routinely.

203 Whenever possible, drug susceptibility testing should be performed for seco

204 Routine drug susceptibility testing should urgently accompany sc

205 nce of bedaquiline resistance and phenotypic drug susceptibility tests should be used to guide and mo

206 Phenotypic and genotypic drug susceptibility testing showed high concordance (91.

207 Drug susceptibility tests showed that biological clones

208 is drug should be first line therapy, unless drug susceptibility testing shows resistance.

209 ciprofloxacin and tetracycline, when a rapid drug susceptibility test that estimates susceptibility t

210 Compared to phenotypic culture-based drug susceptibility testing, the absence of wild-type pr

211 f isoniazid resistance confirms the need for drug susceptibility testing to guide optimal treatment o

212 r both; MDR or XDR tuberculosis confirmed by drug-susceptibility testing to first-line and second-lin

213 ions such as vaccine and common use of rapid drugs susceptibility tests to inform first-line therapy.

214 Drug susceptibility test was done using the Kirby-Bauer

215 low cytometric assay for in vitro antifungal drug susceptibility testing was developed by adapting th

216 Molecular or phenotypic drug susceptibility testing was done locally and at the

217 Drug susceptibility testing was performed by microscopic

218 Molecular drug susceptibility testing was performed on 39 US patie

219 ively known as SIRE), and pyrazinamide (PZA) drug susceptibility testing was performed on 89 clinical

220 Molecular drug susceptibility testing was performed on skin biopsi

221 mmunodeficiency virus (HIV)-infected people, drug susceptibility testing was performed retrospectivel

222 Drug susceptibility testing was performed using the CDC

223 In a subset of 384 isolates with phenotypic drug susceptibility testing, we also observed high sensi

224 diagnostic workflows, phasing out phenotypic drug-susceptibility testing while reporting drug resista

225 The use of a rapid drug susceptibility test with >=50% sensitivity and >=95

226 s study demonstrates that the integration of drug susceptibility testing with genotyping and epidemio

227 ng results of isolation, identification, and drug susceptibility testing within 28 days has increased

228 esistant Mycobacterium tuberculosis requires drug susceptibility testing, yet conventional drug susce